ライフサイエンスコーパス: monoamine oxidase B

1 rmed with 1-PCPA and mammalian mitochondrial monoamine oxidase B.

2 d selective inhibitor of brain mitochondrial monoamine oxidase B.

3 s formed during the bioactivation of MPTP by monoamine oxidase B.

4 g agent, flecainide, which has no recognized monoamine oxidase B activity, and which has previously b

5 example of a biorelevant synthetic model for monoamine oxidase B activity.

6 amine N-methyl transferase) and disposition (monoamine oxidase B and catechol-O-methyl transferase) o

7 Harmol or a combination of monoamine oxidase B and GABA-A receptor modulators exten

8 results reveal that peripheral targeting of monoamine oxidase B and GABA-A receptor, common antidepr

9 ned most (50-60%) of marker enzyme activity, monoamine oxidase-B and porin proteins, but only about 2

10 ltaneous modulation of the targets of harmol monoamine-oxidase B and GABA-A receptor reproduces harmo

11 ic groups that exist in catalytically active monoamine oxidase B are physically distinct.

12 rkinson's disease based on its inhibition of monoamine oxidase B, but the drug is also a potent state

13 volume ([(11)C]SL25.1188 V(T)), an index of monoamine oxidase B density and a marker of astrogliosis

14 We performed a genomewide scan of monoamine oxidase B for the Collaborative Study on the G

15 trate for the flavin-dependent mitochondrial monoamine oxidase B from bovine liver.

16 a targeting enzyme to disrupt the endogenous monoamine oxidase B gene in human cells.

17 Off-target binding to monoamine oxidase B has been overcome, as demonstrated b

18 elective, and reversible inhibitors of human monoamine oxidase B (hMAO-B).

19 onoamine oxidases with slight preference for monoamine oxidase B in both species.

20 hydrogen peroxide (H(2)O(2)) originated from monoamine oxidase B in severe reactive astrocytes causes

21 SKF-38393 had no effects either on total or monoamine oxidase B in the striatum.

22 ng 18F-flortaucipir scanning to test whether monoamine oxidase B inhibition blocked flortaucipir bind

23 We report the effects of the addition of a monoamine oxidase B inhibitor, rasagiline, to antidepres

24 est placebo-controlled clinical trial of the monoamine oxidase B inhibitor, rasagiline, we examined h

25 ploratory subpopulations of PASADENA: use of monoamine oxidase B inhibitors at baseline (yes versus n

26 cipants who were diffuse malignant or taking monoamine oxidase B inhibitors at baseline).

27 2D6 inhibitor, quinidine, and also partly by monoamine oxidase B inhibitors deprenyl and pargyline.

28 Monoamine oxidase B inhibitors result in a mild improvem

29 his, a number of highly potent and selective monoamine oxidase B inhibitors were identified.

30 Monoamine oxidase-B inhibitors and dopamine agonists can

31 In contrast, monoamine oxidase-B inhibitors improved both depressive

32 dowed with potent, selective, and reversible monoamine oxidase B inhibitory activity is a clinically

33 Also, we demonstrate that monoamine oxidase B is an ERRalpha target gene whose exp

34 Results strongly support the presence of monoamine oxidase B-labeled astrogliosis in COVID-DC thr

35 -deuterium-L-deprenyl ((11)C-DED) to measure monoamine oxidase B located in astrocytes.

36 Monoamine oxidase B (MAO B) catalyzes the oxidative deam

37 direct and continuous fluorometric assay for monoamine oxidase B (MAO B) has been developed.

38 The monotopic membrane protein monoamine oxidase B (MAO B) is an important drug target

39 Monoamine oxidase B (MAO B) is an integral protein of th

40 al reversible inhibitors selective for human monoamine oxidase B (MAO B) that do not inhibit MAO A ha

41 ture and subunit composition of bovine liver monoamine oxidase B (MAO B) was investigated using size-

42 (AD), i.e., acetylcholinesterase (AChE) and monoamine oxidase B (MAO B), a series of multitarget lig

43 time-dependent, irreversible inactivators of monoamine oxidase B (MAO B).

44 smokers show a 40% decrease in the level of monoamine oxidase B (MAO B; EC 1.4.3.4) relative to non-

45 A set of drugs was further studied in monoamine oxidase B (MAO-B) and cyclooxygenase-1 (COX-1)

46 mine and compare how two monotopic proteins, monoamine oxidase B (MAO-B) and cyclooxygenase-2 (COX-2)

47 Age-related increases in brain monoamine oxidase B (MAO-B) and its ability to produce r

48 l) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) at the conventional dose (10

49 enosine receptors (A2AARs) and inhibition of monoamine oxidase B (MAO-B) in the brain are considered

50 mined the effects of GM1 ganglioside and the monoamine oxidase B (MAO-B) inhibitor L-deprenyl, alone

51 ine agonists (Frequency ratio 1.4, p=0.058), monoamine oxidase B (MAO-B) inhibitors (Frequency ratio

52 llular model of Parkinson's disease in which monoamine oxidase B (MAO-B) is overexpressed and which e

53 evious finding that smokers have lower brain monoamine oxidase B (MAO-B) levels than comparison nonsm

54 The monoamine oxidase B (MAO-B) substrate properties and dis

55 Monoamine oxidase B (MAO-B) was recently identified as a

56 Illudinine was found to inhibit monoamine oxidase B (MAO-B) with an IC(50) of 18 +/- 7.1

57 e, competitive, and reversible inhibitors of monoamine oxidase B (MAO-B).

58 or (NMDAR), acetylcholinesterase (AChE), and monoamine oxidase B (MAO-B).

59 nt inhibitor of the flavin-containing enzyme monoamine oxidase B (MAO-B).

60 novel radiotracer, [(11)C]SL25.1188, targets monoamine oxidase-B (MAO-B) enzyme, found primarily in a

61 itors of brain carbonic anhydrases (CAs) and monoamine oxidase-B (MAO-B) for the management of Alzhei

62 Monoamine oxidase-B (MAO-B) is a key enzyme in the catab

63 MPTP is converted by monoamine oxidase-B (MAO-B) to its neurotoxic metabolite

64 diographically in conscious mice without the monoamine oxidase B (MAOB) gene (KO, n=11) and the corre

65 was found to suppress the gene expression of monoamine oxidase B (MAOB) in the brain of wild-type but

66 brane domains from the mitochondrial protein monoamine oxidase B (MaoB) or the endoplasmic reticulum

67 known factors in Alzheimer's disease such as monoamine oxidase B (MAOB) protein.

68 tural comparisons with human metabolites and monoamine oxidase B (MAOB) was identified as the putativ

69 Here, we demonstrated elevated levels of monoamine oxidase B (MAOB), a mitochondrial enzyme that

70 oduce the inhibitory gliotransmitter GABA by monoamine oxidase-B (Maob) and abnormally release GABA t

71 ent complex I inhibitor and the two electron monoamine oxidase B oxidation product of MPTP.

72 Monoamine oxidase B, present in the mitochondrial outer

73 ate, decreased benzodiazepine, and increased monoamine oxidase B receptor binding have been reported.

74 Since monoamine oxidase B receptors are expressed by astrocyte

75 nction and these include redox-related genes monoamine oxidase B, ryanodine receptor 2, and glutathio

76 Measuring monoamine oxidase-B with neuroimaging and glial fibrilla